 HEIDELBERG, Germany, Sept. 01, 2022 GLOBE NEWSWIRE -- Affimed N.V. Nasdaq: AFMD Affimed or the Company, a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the Companys management will participate in the following investor conferences during the month of September 2022. 